Abstract
Electrolyte abnormalities are a frequent and potentially hazardous complication in the treatment of patients with congestive heart failure. Medical treatment with diuretics and/or digitalis, as well as neurohumoral activation most likely initiated by the compromised cardiac function, contributes to this alteration. The addition of potassium- and magnesium-sparing diuretics (triamterence, amiloride) to therapy with frusemide or hydrochlorothiazide is of possible value in preventing intracellular electrolyte abnormalities.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Aged, 80 and over
-
Digoxin / therapeutic use
-
Double-Blind Method
-
Drug Therapy, Combination
-
Erythrocytes / metabolism
-
Furosemide / therapeutic use
-
Heart Failure / blood
-
Heart Failure / drug therapy*
-
Humans
-
Hydrochlorothiazide / therapeutic use
-
Intracellular Fluid / chemistry
-
Lymphocytes / metabolism*
-
Magnesium / blood*
-
Middle Aged
-
Potassium / blood*
-
Triamterene / pharmacology*
Substances
-
Hydrochlorothiazide
-
Digoxin
-
Furosemide
-
Magnesium
-
Potassium
-
Triamterene